Upstream Bio (UPB) Accumulated Depreciation & Amortization (2023 - 2026)
Upstream Bio's quarterly Accumulated Depreciation & Amortization came in at $393000.0 in Q1 2026, up 97.49% year-on-year from $199000.0 in Q1 2025, and up 14.24% quarter-over-quarter from $344000.0 in Q4 2025.
Upstream Bio has reported Accumulated Depreciation & Amortization for 4 years, with the latest figure at $393000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Depreciation & Amortization rose 97.49% year-over-year to $393000.0; the trailing twelve-month figure through Mar 2026 stood at $393000.0 (up 97.49% YoY), and the FY2025 full-year result was $344000.0, up 120.51% from the prior year.
- Accumulated Depreciation & Amortization for Q1 2026 stood at $393000.0, up from $344000.0 in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $393000.0 in Q1 2026, with the low at $67000.0 in Q4 2023.
- Average Accumulated Depreciation & Amortization over 4 years is $224250.0, with a median of $220000.0 recorded in 2025.
- Year-over-year, Accumulated Depreciation & Amortization soared 168.22% in 2025 and jumped 97.49% in 2026.
- Tracing UPB's Accumulated Depreciation & Amortization over 4 years: stood at $67000.0 in 2023, then soared by 132.84% to $156000.0 in 2024, then soared by 120.51% to $344000.0 in 2025, then grew by 14.24% to $393000.0 in 2026.
- The last three Accumulated Depreciation & Amortization figures came in at $393000.0 (Q1 2026), $344000.0 (Q4 2025), and $287000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 393,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Dec 31, 2025 | 344,000.00 |
| Dec 31, 2025 | 344,000.00 |
| Sep 30, 2025 | 287,000.00 |
| Sep 30, 2025 | 287,000.00 |
| Jun 30, 2025 | 241,000.00 |
| Jun 30, 2025 | 241,000.00 |
| Mar 31, 2025 | 199,000.00 |
| Mar 31, 2025 | 199,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Dec 31, 2024 | 156,000.00 |
| Sep 30, 2024 | 107,000.00 |
| Sep 30, 2024 | 107,000.00 |
| Dec 31, 2023 | 67,000.00 |
| Dec 31, 2023 | 67,000.00 |